Since the immune system in BC patients is dysfunctional [269], targeting the IDO site is an alternative option for repopulating the host with immune cells, relieving IDO-mediated immune suppression in the TME and tumor cells themselves [270]. This evidence concerns the gene IDO1 and neoplasm.